ALXO ALX Oncology Holdings Inc.
Financings ·
ALX Oncology's exchange trades 13,353,384 common shares for pre-funded warrants with a $0.001 exercise price, and the 8-K describes no cash payment to the company.
ALX Oncology borrowed $10,000,000 at closing from HSBC Ventures USA and used it to refinance its Oxford Finance and Silicon Valley Bank loan. The facility can reach $50,000,000, but $10,000,000 of that is uncommitted and the rest depends on draw dates and milestones.
ALX Oncology priced 76,979,112 shares and pre-funded warrants for 18,574,120 more, at $1.57 a share, after a year of failed or dropped combination trials and a narrower focus on its CD47 drug evorpacept.
ALX Oncology's board approved a cut of about 30% of staff on Feb 28, 2025, and eliminates its president and chief scientific officer role. The company estimates about $2.2 million in severance and benefits for a lead drug that has not completed a pivotal trial.
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company developing novel therapies to treat cancer. Its lead product candidate, evorpacept, is a CD47 blocker that combines a high-affinity CD47 binding domain with a proprietary inactivated Fc domain. The company designs evorpacept for combination with other anti-cancer agents that provide a positive immune-stimulating signal, and says that clinical data to date have not shown the dose-dependent hematologic toxicities seen with other CD47 blockers that have an active Fc domain. Evorpacept is being evaluated with trastuzumab and chemotherapy in patients with metastatic HER2-positive breast cancer in the Phase 2 ASPEN-09-Breast trial. The company describes the randomized ASPEN-06 Phase 2 trial in gastric cancer as supporting the clinical validation of this mechanism. The company says approximately 800 subjects have been treated with evorpacept in combination with targeted anti-cancer agents, small molecules and checkpoint inhibitors. Its second pipeline candidate, ALX2004, is an EGFR-targeted antibody-drug conjugate that entered a Phase 1 clinical trial in August 2025.
| Product or program | What it is | Stage |
|---|---|---|
| Evorpacept | CD47 blocker fusion protein for cancers that over-express CD47, used in combination therapy | Phase 2 (ASPEN-09-Breast) |
| ALX2004 | EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action | Phase 1 trial entered in August 2025 |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $77.0 million | $116.4 million |
| Net income (loss) | -$101.7 million | -$134.8 million |
| Cash from operations | -$84.1 million | -$121.9 million |
| Cash and equivalents | $16.4 million | $17.6 million |
| Short-term investments | $28.4 million | $110.2 million |
Opinion Mixed view
Our arithmetic gives about 23 months, close to the company's first half of 2028 date. The best response rate comes from a 43-patient subgroup, and the FDA has said the gastric data cannot support accelerated approval.
Our latest story on this, dated Jan 30, 2026: "ALX Oncology raises $150 million at $1.57 a share, led by RA Capital and TCGX". The story links the filing or release it is based on. Read the story.
ALX Oncology Holdings Inc. trades under the ticker ALXO on NASDAQ.
ALX Oncology Holdings Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for ALX Oncology Holdings Inc. is 1810182. Its filings are on SEC EDGAR.
138,276,997 shares as of 2026-07-30, per the cover page of its 10-Q filed 2026-08-06.
Our directory records ALX Oncology Holdings Inc. under United States.
Our directory classifies ALX Oncology Holdings Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for ALX Oncology Holdings Inc. is US00166B1052.
aibio.space lists ALX Oncology Holdings Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company developing novel therapies to treat cancer. Its lead product candidate, evorpacept, is a CD47 blocker that combines a high-affinity CD47 binding domain with a proprietary inactivated Fc domain.
Evorpacept: CD47 blocker fusion protein for cancers that over-express CD47, used in combination therapy Stage: Phase 2 (ASPEN-09-Breast).
ALX2004: EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action Stage: Phase 1 trial entered in August 2025.
ALX Oncology Holdings Inc. reported a net loss of $101.7 million for the fiscal year ended Dec 31, 2025, and used $84.1 million of cash in operations, per its annual report to the SEC.
$77.0 million in the fiscal year ended Dec 31, 2025, per its annual report.
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02,2.03,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,5.02). Source
Offered to buy back its own securities. SEC Form SC TO-I. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio